
Daily Derm Times: July 7, 2025
Key Takeaways
- Whole-body cryotherapy shows potential as a non-pharmacologic treatment for atopic dermatitis, offering inflammation relief.
- APG777, an anti-IL-13 antibody, demonstrates high efficacy in moderate to severe atopic dermatitis, achieving significant EASI-75 response rates.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Cold Therapy May Relieve Inflammation in AD
Explore the potential of whole-body cryotherapy as a novel, non-pharmacologic treatment for managing atopic dermatitis symptoms effectively.
APG777 Demonstrates High EASI-75 Response Rates in Moderate to Severe Atopic Dermatitis
New 16-week data from the phase 2 APEX clinical trial demonstrated the anti-IL-13 antibody's efficacy across all key endpoints.
Laser Therapy Gains Ground in Acne Management
Discover the latest advancements in laser treatments for acne vulgaris, focusing on diverse skin types and effective solutions for acne skin of color.
VYNE Unblinds Early VYN202 Data After Safety Pause
VYNE Therapeutics updates on VYN202, revealing promising early results in psoriasis treatment despite a clinical hold due to safety concerns.
Dermatology Times' Weekly Crossword: July 7, 2025
Test your knowledge of key words and terms associated with dermatology news from the previous week.
Beyond the Label: Evaluating Bimekizumab’s Mental Health Profile in Psoriasis Treatment
Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















